<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESTRAMUSTINE PHOSPHATE SODIUM</span><br/>(ess-tra-muss'teen)<br/><span class="topboxtradename">Emcyt<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>140 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Conjugate of estradiol and the carbamate of nitrogen mustard. Extent of antitumor activity contributed by each, as well as
         precise mechanisms of action, unknown.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Appears to act as a relatively weak alkylating agent and estrogen. Major effectiveness reported to be in patients who have
         been refractory to estrogen therapy alone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment of metabolic or progressive carcinoma of prostate.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to either estradiol or nitrogen mustard; active thrombophlebitis or thromboembolic disorders; pregnancy (category
         X), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of thrombophlebitis, thromboses, or thromboembolic disorders; cerebrovascular or coronary artery disease; gallstones
         or peptic ulcer; impaired liver function; metabolic bone diseases associated with hypercalcemia; diabetes mellitus; hypertension,
         conditions that might be aggravated by fluid retention (e.g., epilepsy, migraine, kidney dysfunction); older adult patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Neoplasm</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 14 mg/kg/d in 34 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals to reduce incidence of GI adverse effects. Some patients require drug withdrawal because of intolerable GI
            effects.
         </li>
<li>Store at 2°8° C (38°46° F) in tight, light-resistant containers, unless otherwise directed
            by manufacturer.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Lethargy, emotional lability, insomnia, headache, anxiety. <span class="typehead"> CV:</span> CVA, <span class="speceff-life">MI</span>, <span class="speceff-common">thrombophlebitis,</span> CHF, <span class="speceff-common">peripheral edema.</span> <span class="typehead"> GI:</span> <span class="speceff-common">Nausea,</span> diarrhea, anorexia, flatulence, vomiting, thirst, GI bleeding. <span class="typehead">Hematologic:</span> Leukopenia, thrombocytopenia, <span class="speceff-common">abnormalities in liver function tests,</span> hypercalcemia, <span class="speceff-life">bone marrow depression</span> (rare). <span class="typehead">Respiratory:</span> Hoarseness, burning sensation in throat, dyspnea, upper respiratory discharge, <span class="speceff-life">pulmonary emboli</span>. <span class="typehead">Skin:</span> Rash, pruritus, urticaria, dry skin, easy bruising, flushing, peeling skin and fingertips, thinning hair. <span class="typehead">Special Senses:</span> Tearing of eyes. <span class="typehead">Urogenital:</span> Gynecomastia, breast tenderness, impotence. <span class="typehead">Endocrine:</span> Decrease in glucose tolerance. <span class="typehead">Musculoskeletal:</span> Leg cramps. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Food:</span> Milk, dairy products, calcium supplements may decrease estramustine absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span>  23 h. <span class="typehead"> Metabolism:</span>  Dephosphorylated in intestines to estramustine, estradiol, estrone, and nitrogen mustard; further metabolized in liver. <span class="typehead">Elimination:</span> Excreted in feces via bile. <span class="typehead">Half-Life:</span> 20 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight and examine for peripheral edema. Be mindful that drug can cause CHF.</li>
<li>Monitor I&amp;O ratio and pattern to prevent dehydration and electrolyte imbalance, especially with vomiting or diarrhea.</li>
<li>Observe diabetics closely because of possibility of estramustine-induced reduction in glucose tolerance. Monitor baseline
            and periodic glucose tolerance tests.
         </li>
<li>Lab tests: Perform baseline and periodic liver enzymes and bilirubin tests; repeat after drug has been discontinued for 2
            mo.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Eat small meals at frequent intervals to reduce drug-induced nausea, eat slowly, and try cold food if food odors are offensive.</li>
<li>Drink liquids 1 h before or 1 h after rather than with meals; clear liquids may be more palatable.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>